Neutrophils are innate immune cells known to provide mucosal protection against bacterial and fungal pathogens.1 As the first leukocytes recruited to sites of acute infection and inflammation, neutrophils display a broad range of functions, including direct pathogen killing, release of inflammatory mediators, immune cell recruitment, and tissue remodeling.2,3

Neutrophils inactivate pathogens through multiple mechanisms, including phagocytosis, degranulation, and NETosis.1 NETosis is characterized by the extrusion of neutrophil extracellular traps (NETs), consisting of DNA fragments associated with granular proteins with antimicrobial activity.4 NETs are released through an active process to inactivate a wide range of bacterial and fungal pathogens in vitro and in vivo.4,5,6,7 While aberrant chronic NETosis and acute NETosis induced under sterile conditions are thought to contribute to pathology,3,8,9 acute vital NETosis against infectious agents has been proposed as an efficient defense mechanism that prevents collateral tissue damage by concentrating antimicrobials and reducing protease toxicity.6,10,11,12

Recently, blood neutrophils were reported to release NETs and inactivate human immunodeficiency virus (HIV) in vitro,13 providing evidence that neutrophils have the ability to recognize and inactivate HIV. However, the role of NETosis in protection against HIV infection at mucosal sites remains a gap in our knowledge. In the context of HIV prevention, location is key,14 since NET inactivation of HIV in the genital mucosa has the potential of preventing HIV acquisition.

Genital neutrophils are present throughout the female genital tract,15 and are phenotypically and functionally different than those found in blood.16 Neutrophils are present within the stratified epithelium of the vagina17 and on the mucosal surfaces of the genital tract, where they can be recovered by cervico-vaginal lavage or cytobrush.18 Neutrophils are also abundant in the endometrium, where they play a critical role in tissue remodeling during menstruation.19 Further, because of their first-responder nature, neutrophils are rapidly recruited to sites of injury,20 and potential viral entry.

Supporting clinical evidence for a role of neutrophils in preventing HIV transmission comes from clinical studies analyzing the association between low neutrophil counts, a frequent condition in Africa, and HIV acquisition risk.19,20 Kourtis et al.21 demonstrated increased intrauterine perinatal transmission of HIV in mothers with lower neutrophil counts, while Ramsuran et al.22 reported increased risk of HIV acquisition in female sexual workers with neutropenia and high platelet counts. In contrast, studies performed in the context of sexually transmitted infections (STIs) and inflammation, both generally associated with neutrophil recruitment, report associations between increased risk of HIV acquisition and the presence of neutrophil-derived molecules in cervico-vaginal secretions.23,24,25 These apparently contradictory findings highlight the gap in our knowledge about neutrophil mucosal responses to HIV and the need to determine the role of NETosis in HIV acquisition.

Due to their location, both in the stroma beneath the epithelial layer and on mucosal surfaces,17,18 it is likely that neutrophils are among the first cells to encounter HIV after genital viral exposure. Despite their abundance throughout the human genital tract,15 their distinct characteristics when compared to blood neutrophils,16 and crucial contribution to innate immunity at mucosal surfaces, the direct role of genital neutrophils in HIV protection remains a gap in our knowledge.


Genital neutrophils entrap HIV in NETs

We recently demonstrated that genital dendritic cells (DCs) expressing CD11b and CD14 had specific HlV-capture potential.26 While investigating HIV capture in genital mixed-cell suspensions, we observed that neutrophils also rapidly captured HIV viral-like particles (HIV-VLPs) (Fig. 1a), with 3–4-fold more efficacy than DCs (Fig. 1b). Enhanced HIV capture by neutrophils from the ectocervix (ECX) and endocervix (CX) was observed in five out of six patients, and from the endometrium (EM) in all patients studied (Fig. 1b). Unexpectedly, fluorescence microscopy analysis revealed high concentration of HIV-VLPs in extracellular DNA structures (Fig. 1c). Since one previous report demonstrated that NETs from blood neutrophils capture HIV,13 we investigated if genital neutrophils could release NETs in response to HIV. Purified genital neutrophils (Fig. 1d) were stimulated with HIV-VLPs or with calcium ionophore, a known inducer of NETs,27 as a positive control. NETs were detected after HIV-VLP (Fig. 1e), or calcium ionophore (Fig. 1f) stimulation, demonstrating that neutrophils from the genital tract have the ability to release NETs.

Fig. 1
figure 1

Genital neutrophils entrap HIV in NETs. a Representative example of the gating strategy to identify neutrophils after stimulation with HIV-VLP-GFP. Neutrophils were identified as CD45+, SSC-Ahi, and CD11bhi. Parallel unstimulated controls showed that this population was also CD15+CD66b+. b Comparison of HIV-VLP capture by neutrophils (black dots) or CD14+ dendritic cells (DCs; white dots) in the same tissues from the ECX, CX, and EM from six different women; matching ECX, CX, and EM were obtained from each patient. Mann–Whitney U test. *p < 0.05; **p < 0.01. c Representative image of HIV-VLP accumulation (GFP, green) in extracellular DNA structures (DAPI) 1 h after stimulation of mixed-cell suspensions with HIV-VLP. Bottom row shows unstimulated controls. Scale bar = 200 µm. d Representative example of purity following magnetic bead selection of genital neutrophils. Purified neutrophils show characteristic nuclear morphology and surface expression of CD15 and CD66b by confocal microscopy. e Representative image of the formation of NETs (stained with the nucleic acid dye Sytox) following stimulation with HIV-VLP (GFP, green) (scale bar = 20 µm) or (f) calcium ionophore, using confocal microscopy (scale bar = 5 µm)

Genital neutrophils actively release NETs within minutes after HIV exposure

To characterize the dynamics of HIV entrapment by NETs, we optimized a system to visualize NETosis in real time using time-lapse imaging. Mixed-cell suspensions from ECX, CX, and EM were cultured in media containing cell impermeant DNA-dye (red) and stimulated with green fluorescent protein (GFP)-tagged HIV-VLPs (green). When DNA is released into the extracellular compartment, red signal is visualized. Conversely, HIV-VLPs can be detected as green signal. As seen in Fig. 2a, using this system, we detected neutrophil release of DNA (NETs; red) into the extracellular compartment and HIV-VLP entrapment (green). NET release and HIV-VLP capture occurred within minutes of viral stimulation, and continued for approximately 30 min, but new NETosis and HIV-VLP capture was infrequent after that (Fig. 2b and Supplementary videos 1 and 2). As a control, the addition of DNAse in combination with HIV-VLP to the culture media abolished the formation of NETs (Fig. 2b, white circles; Supplementary video 3). Analysis of NET area in different patients demonstrated a significant increase in extracellular DNA release in the presence of HIV-VLPs (Fig. 2c). Importantly, comparison of neutrophils from blood and genital tissues demonstrated increased NET release by genital neutrophils following HIV stimulation (Fig. 2d). This difference remained significant after excluding from the analysis one outlier data point in the tissue data set (p < 0.045). This suggests that mucosal-specific factors influence NETosis capacity of neutrophils, and represents further evidence that genital neutrophils are distinct from blood.16

Fig. 2
figure 2

Genital neutrophils actively release NETs within minutes after HIV exposure. a Representative image of NET formation and co-localization with HIV-VLP as visualized using the IncuCyte Zoom system. b Representative example of quantification of NET release over time in mixed-cell suspensions from ECX, CX, and EM from the same woman. Total NET area is represented and reaches maximum magnitude between 15 and 30 min after stimulation. Curves from unstimulated controls (triangles) and DNAse + HIV-VLP-treated samples (white circles) overlap at the bottom. c Fold change in NET area in HIV-VLP-stimulated samples with respect to unstimulated controls. Maximal NET area within the first hour is represented for each individual. Each dot represents a different woman, and includes unmatched samples from ECX, CX, and EM. Wilcoxon's signed-rank test. d Total NET area after stimulation of genital neutrophils or blood neutrophils with HIV-VLPs. Shown are the mean values of every time point within the first 30 min after subtracting the background signal from unstimulated controls. Each dot represents a different individual. Mann–Whitney U test. e Total NET-HIV area in matched samples from ECX, CX, and EM. The mean value of all the time points within the first 30 min are shown for HIV-stimulated samples (HIV-VLP) and unstimulated controls. Wilcoxon's matched-pairs signed-rank test; n = 10. f Dose–response studies with increased levels of HIV-VLP per cell. Each dot represents a different tissue, including unmatched ECX, CX, and EM. Kruskall–Wallis with Dunn's post-test; n = 14. g DNAse treatment in addition to HIV-VLP diminished NET-HIV complex area. Each dot represents a different tissue, including unmatched ECX, CX, and EM. Mann–Whitney U test; n = 7

To quantify HIV capture, coincident red (NET) and green (HIV-VLP) signals were measured. NET-HIV complexes were detected in all genital sites, with no differences between ECX, CX and EM (Fig. 2e). HIV capture was dose-dependent, with increased number of HIV-VLP per cell resulting in greater induction of NET-HIV complexes (Fig. 2f). Furthermore, DNAse treatment significantly reduced viral capture (Fig. 2g), demonstrating that HIV-VLP entrapment is mediated by DNA.

Overall, these data demonstrate that HIV stimulates genital neutrophils to release NETs in a time-dependent and dose-dependent manner, to entrap and immobilize HIV at different sites in the genital tract.

NETs from genital neutrophils inactivate HIV and prevent infection of CD4+ T cells

Next, we investigated if HIV entrapment in NETs would result in viral inactivation. To do this, we generated NETs by stimulation of purified genital neutrophils with calcium ionophore, and isolated NETs by centrifugation.28 As a control for background extracellular DNA not generated through NETosis, unstimulated neutrophils were incubated with dimethyl sulfoxide (DMSO) and centrifuged in the same way as calcium ionophore-stimulated neutrophils. Isolated NETs or DNA control were then incubated with HIV for 1 h, prior to the addition of activated CD4+ T cells to measure infection as described in Methods. As shown in Fig. 3a, using fluorescent microscopy to detect HIV-infected GFP+ cells 7 days after infection, HIV-infected T cells were abundant in the control condition (green), but undetectable when NETs from ionophore-stimulated neutrophils were present. Additionally, NET inhibition of productive HIV infection was confirmed by measuring released p24 by enzyme-linked immunosorbent assay (ELISA) 3 and 7 days after infection (Fig. 3b). Productive HIV infection was observed in the control condition, but absent when NETs were present (Ionophore stimulation). To investigate whether reduced infection was a result of viral inactivation or immobilization by NETs, DNAse was added to HIV-NET complexes to degrade the NETs and release potentially infectious virions. As shown in Fig. 3b (white bars), DNAse treatment to release trapped virus did not increase HIV infection. Quantification of viral suppression in different individuals in the presence of NETs demonstrated almost complete inhibition after 7 days (Fig. 3c). These findings indicate that HIV is irreversibly inactivated by NET contact. Overall, these results demonstrate that NETs from genital neutrophils inactivate HIV and prevent infection of target cells.

Fig. 3
figure 3

NETs from genital neutrophils inactivate HIV and prevent infection of CD4+ T cells. a Representative microscopy image of HIV-infected CD4+ T cells (GFP+) 7 days after infection, in the control condition with no NETs present (control DNA) and when purified isolated NETs were present. b Levels of p24 as determined by ELISA in the culture supernatants 3 days (D3) and 7 days (D7) after infection, in the absence (control) or presence of pre-formed NETs. Experiments were performed in the absence of DNAse (black bars) or presence of DNAse (white bars) after incubation of NETs with HIV to degrade NETs and release any potentially infectious virions. Bars show one representative example run in triplicates. c Percent of inhibition of HIV infection in the NET condition relative to the control condition. One hundred percent inhibition means the absence of detectable infection. Each dot represents a different patient source for NETs. One-sample t test; n = 4

Different HIV strains, HIV lacking envelope, and TLR7/8 ligands induce NETosis of genital neutrophils

To gain insight into the mechanisms by which HIV induces NETosis of genital neutrophils, mixed-cell suspensions were stimulated with HIV-VLPs with different envelope glycoproteins (BaL and NL43) or lack thereof (delta-Env). The three types of HIV-VLPs induced NETosis and the formation of NET-HIV complexes (Fig. 4a), suggesting that the envelope glycoproteins are not required for NETosis induction.

Fig. 4
figure 4

Different HIV strains, HIV lacking envelope, and TLR7/8 ligands induce NETosis of genital neutrophils. a NET-HIV complexes were induced after stimulation with HIV-VLP encoding envelope glycoproteins from BaL (R5), NL43 (X4), and lack of envelope (∆-env). The mean value of the area in the first 30 min is represented. Mixed-cell suspensions from each tissue were stimulated with the three different viral constructs; each dot represents a different patient. Kruskall–Wallis with Dunn's post-test for multiple comparison correction; n = 10. ***p < 0.0001; **p < 0.01. b Dose–response studies of the release of DNA after stimulation with ssRNA40, a TLR7/8 ligand. Bars represent fluorescence intensity of Sytox Orange after 1 h stimulation. *P < 0.05. c Representative confocal microscopy image of NET formation after stimulation with ssRNA40 (15 µg/ml) for 1 h (scale bar = 20 µm). d Time-course curve of the NET total area after stimulation with HIV-VLP BaL, NL43, or ∆-env in the absence (control; black diamonds) or presence of DPI (white diamonds). Lines in the x axis are separated by 3 min intervals. e NET-HIV area in the absence (control; black bars) or presence of DPI (white bars). Bars represent the mean value of total NET-HIV area between each indicated time point. Time 0 shows the background before the addition of HIV-VLPs. HIV-VLP BaL = 8; NL43 = 6; ∆-env = 4. Mann–Whitney test. **p = 0.0078; *p < 0.05

Given that HIV-VLPs lacking envelope triggered NETosis, and that Toll-like receptor (TLR) stimulation is a common pathway for NETosis induction,5,6,13 we investigated whether HIV-derived TLR stimulation would induce NETosis of genital neutrophils. Mixed-cell suspensions were stimulated with the TLR7/8 ligand ssRNA40, a single-stranded RNA derived from the HIV-1 long-terminal repeat. Stimulation with ssRNA40 induced DNA release, measured as increased fluorescence intensity, in a dose-dependent manner (Fig. 4b). Confocal microscopy of purified genital neutrophils confirmed the induction of NETs after ssRNA40 stimulation (Fig. 4c). This finding is consistent with previous reports demonstrating activation of blood neutrophils by TLR7/8 ligands,13,29 and indicates that TLR signaling is a potential pathway for HIV-induced NETosis in genital neutrophils.

NETosis have been described to be mediated through reactive oxygen species (ROS)-dependent and ROS-independent pathways.30 To investigate if HIV induction of NETs involved ROS-dependent mechanisms, genital neutrophils were incubated with diphenyleneiodonium (DPI), a known inhibitor of ROS,30 prior to HIV stimulation. As shown in Fig. 4d, when neutrophils were stimulated with HIV-VLP containing envelope glycoproteins (BaL or NL43), initial events of NETosis (<30 min) were independent of ROS, but were ROS dependent at latter time points. In contrast, NETosis in response to HIV-VLP lacking envelope was more sensitive to ROS inhibition, with a 50% reduction in the initial magnitude of NETosis. The temporal dynamics of reduction in NETosis correlated with reduced HIV-NET complexes in the DPI treatment condition after 30 min of stimulation (Fig. 4e). These results demonstrate that the initial triggering of NETosis is ROS independent and partially driven by the envelope, while ROS-dependent mechanisms are important for the maintenance of the process.


Overall, our study demonstrates that genital neutrophils recognize HIV and release NETs that inactivate the virus, preventing subsequent infection of HIV-susceptible cells. HIV entrapment and inactivation by NETs is rapid (within minutes) and irreversible, appearing as an efficient mechanism to prevent mucosal HIV acquisition after sexual contact.

While previous data demonstrating HIV inactivation by NETs from blood neutrophils may be relevant for immunotherapeutic strategies in patients chronically infected with HIV,13 our findings are particularly relevant for the prevention of HIV acquisition in the female genital mucosa, and possibly at other mucosal sites in the body. First, we used neutrophils from different anatomical compartments in the female genital tract, which are modified by the tissue environment,16 and represent the very cells that will be exposed to HIV after sexual intercourse. Second, we demonstrate that HIV induction of NETs occurs both with purified genital neutrophils and in the context of genital mixed-cell suspensions, which include tissue-resident DCs and other mucosal cells, mimicking the mucosal cell environment. This is in contrast to the findings of Saitoh et al.13 using blood monocyte-derived DCs, who postulated that NETosis would be counteracted by HIV through actions on DCs and interleukin-10 (IL-10) induction. Our results indicate that mucosal NETosis in response to HIV will not be counteracted, given the rapidity of NETosis induction, and our previous observation that genital DCs do not produce IL-10 within the first 3 h after HIV stimulation.26 Third, NETs from genital neutrophils are released within minutes of viral exposure, and infrequent after 30 min, suggesting an acute self-controlled mechanism unlikely to induce tissue damage. Importantly, irreversible inactivation of HIV, as seen in our study, would prevent infection of any susceptible cell that may be attracted to HIV-NET complexes by chemotactic molecules released by neutrophils during their activation.

From a mechanistic standpoint, our findings suggest that HIV induces neutrophil NETosis through at least two different mechanisms. Our results that HIV-VLPs lacking envelope induce NETosis are consistent with TLR7/8 stimulation by viral RNA. Additionally, it is likely that the envelope glycoproteins act through ROS-independent pathways to modulate the initial magnitude of NET release. Whereas our results confirm that late events of HIV-induced NETosis are ROS dependent;13 they add a new dimension by demonstrating that triggering and early events of NETosis in response to HIV are ROS independent, as reported for other pathogens.5,31

Our demonstration that HIV inactivation by NETs occurs in vitro, provides a solid foundation to further examine the interactions of neutrophils with other immune cells in the female genital tract both in tissue explants and in vivo animal models. While we postulate that NETosis is an important protective mechanism in healthy women, further studies are needed to define the protective role of NETs against HIV acquisition in the context of STIs, which are known to damage epithelial cells and recruit HIV target cells to sites of infection. In addition, sexually transmitted pathogens induce neutrophil degranulation and phagocytosis (which may inhibit NETosis pathways),32 and display multiple mechanisms to evade neutrophil-mediated immunity, including inhibition of NETs killing (Neisseria gonorrhea),33,34,35,36 inactivation of antimicrobials (Chlamydia trachomatis),37,38 and induction of neutrophil apoptosis (Trichomonas vaginalis).39 Future studies are needed to test the hypothesis that interference of sexually transmitted pathogens with NETosis and anti-HIV activity in NETs may represent an unrecognized contributing factor for increased risk of HIV acquisition.

Our studies extend the findings of others that neutrophils, in addition to playing an important by-stander role in inflammation,23,24,25 are unrecognized effector cells with the ability to directly inactivate HIV. NETosis of genital neutrophils in response to HIV may represent a constitutive baseline protection mechanism contributing to the low transmission rate per sexual act described in epidemiological studies.40 However, recognizing that neutrophils are present under conditions known to increase susceptibility to HIV infection (i.e., genital inflammation, epithelial disruption or genital infections), future studies are needed to determine the multiple factors that may shift the balance from neutrophil-mediated viral inactivation to inflammation and increased risk of HIV acquisition. Given that neutrophils are present in the genital tract under physiological conditions,15,16,17 but can also be rapidly recruited and activated under pathological conditions, it is possible that neutrophils play separate and distinct roles in HIV acquisition under different circumstances.

Our findings challenge the current model of mucosal HIV acquisition, by demonstrating that genital neutrophils, not previously considered to interact with HIV at mucosal surfaces or to play a role in protection, respond within minutes to viral exposure to prevent HIV infection of target cells. Recognizing that the initial interactions between HIV and the immune system in the genital tract have the potential to prevent infection of target cells and HIV acquisition,14 our findings may represent a previously unrecognized mechanism of mucosal protection that can aid the development of effective prevention strategies for women.


Study subjects

Written informed consent was obtained before surgery from HIV-negative women undergoing hysterectomies at Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA). Studies were approved by Dartmouth College Institutional Review Board and the Committee for the Protection of Human Subjects. Surgery was performed to treat benign conditions, including fibroids, prolapse, and menorrhagia. Hormonal contraceptives were not administered before surgery. Trained pathologists selected tissue samples from ECX, CX, and EM, free of pathological lesions and distant from the sites of pathology. Women used in this study were premenopausal, HIV negative and human papillomavirus negative, but no additional information regarding other genital infections was available.

Tissue processing

For comparisons between different anatomical sites, matched tissues from the ECX, CX, and EM of the same patient were used whenever possible as indicated. In some cases, only endometrial tissue was provided by pathology. Vaginal tissues were not available. Tissues were generally processed within 6 h after surgery. In exceptional cases of late surgery, tissues were kept overnight at 4 °C and processed in the morning. Tissues were processed to obtain a stromal cell suspension as described previously,26,41,42,43 using 0.05% collagenase type IV (Sigma-Aldrich, St. Louis, MO, USA) and 0.01% DNAse (Worthington Biochemical, Lakewood, NJ, USA). After filtering through a 20 µm mesh screen (Small Parts) to separate epithelial cells from stromal cells, cell preparations underwent dead cell removal (Dead Cell Removal Kit, Miltenyi Biotech) as described,41 resulting in more than 90% cell viability by trypan blue staining. After dead cell removal, mixed-cell suspensions were used for NETosis experiments as indicated, or underwent further processing to purify neutrophils.

Neutrophil purification

Stromal mixed-cell suspensions were further purified by standard Ficoll density gradient centrifugation to separate mononuclear cells, which remained above the Ficoll. After red blood cell lysis, genital neutrophils were purified from the pellets by magnetic bead selection with the CD66abce Microbead Kit (Miltenyi Biotec). Following two rounds of selection, purity of the population was >88% as determined by flow cytometry (Fig. 1d). Characteristic neutrophil morphology was confirmed with confocal microscopy (Fig. 1d).

Neutrophils from blood were isolated with whole blood CD15 microbeads and whole blood column kit following instructions (Miltenyi Biotec). The purity of the population was >95%.

Generation of GFP-labeled VLPs

A modified pNL43 provirus-based plasmid for expression of GFP-labeled VLPs and encoding NL43 Env in cis (referred to as K795) was described previously.44 Briefly, the enhanced GFP (EGFP) coding sequence is expressed in frame at the 3′ end of gag, replacing the protease and most of reverse transcriptase coding region. The Ψ-signal on the RNA and the entire gag open reading frame remain intact. In addition, a plasmid in which the env orf was inactivated, and from which no functional Env is expressed (referred to as K806) was derived from K795 for pseudotyping, and complemented with pBaL.26 Env expression plasmid (NIH AIDS Reagent program, catalog number 11446, contributed by Dr. John Mascola).45 VLPs which are EGFP labeled and non-infectious were produced by transfection, concentrated by ultracentrifugation, and enumerated essentially as described.44

Viral capture assay

As described previously,26 mixed-cell suspensions were incubated with HIV-GFP VLPs carrying R5 env proteins at a concentration of 10,000 VLPs per cell for 1 h at 37 °C. Following incubation, cells were washed to remove unbound VLPs and stained for flow cytometric analysis. Viral capture is shown as the percentage of GFP+ cells in the appropriate DC or neutrophil gates, according to the antibodies described below.

Flow cytometry

Mixed-cell suspensions were stained for surface markers with combinations of the following antibodies: CD45-vioblue450, CD11b-PE (Tonbo, San Diego, CA, USA), CD3-VioGreen, CD15-FITC, CD66b-APC (Miltenyi Biotec), CD11c-PerCp-Cy5.5, CD1c-PE-dazzle, HLA-DR-BV570, CD3-APC (BioLegend), and CD14-e780, (eBiosciences, San Diego, CA, USA). Dead cells were excluded with 7-aminoactinomycin D (Southern Biotech) or zombie dye yellow staining (BioLegend). Analysis was performed on 8-color MACSQuant 10 (Miltenyi Biotech) or Gallios (Beckman Coulter, Indianapolis, IN, USA) flow cytometers and data were analyzed with the FlowJo software (Tree Star, Inc., Ashland, OR, USA). Expression of surface markers is shown as the percentage of positive cells. Fluorescence minus one strategy was used to establish appropriate gates. Cells were gated as described before.26

NET induction and confocal microscopy

Purified genital neutrophils were re-suspended in Hank's balanced salt solution (HBSS) containing Sytox orange nucleic acid stain (Molecular Probes, Eugene, OR, USA) and plated on coverslips. HIV-VLP-GFP-labeled (5000 VLP per cell, unless otherwise specified), calcium ionophore A23187 (Sigma), or ssRNA40 (InvivoGen, San Diego, CA, USA) were used to stimulate NETosis for 1 h at 37 °C. Unstimulated neutrophils incubated in HBSS with Sytox orange were used as unstimulated controls. Cells were carefully washed with HBSS, and samples were mounted in Pro-Long Diamond anti-fade mountant with DAPI (4',6-diamidino-2-phenylindole; Thermo Fisher Scientific). Samples were imaged using a Zeiss LSM 510 laser-scanning confocal microscope in combination with the Zeiss Zen software.

Time-lapse microscopy of NETs

Mixed-cell suspensions or purified neutrophils as indicated were plated in flat-bottom 96-well plates in HBSS containing Incucyte Cytotox red reagent (Essen Bioscience, Ann Arbor, MI, USA), a cell-impermeant DNA stain. HIV-VLP-GFP labeled were added to the cells and the plate was imaged using the Incucyte Zoom system (Essen Bioscience) with ×10 objective. Images were collected every 2–3 min and fluorescent signal quantified with the Incucyte Zoom software.

Quantification of NETs and HIV-NET complexes

To quantify NETs, total area of fluorescent red signal (Cytotox red) was quantified. A mask was established with size constrictions based on negative controls treated with DNAse to exclude intracellular red signal (potential dead cells, not NETs). To measure HIV capture, NET-HIV complexes were quantified as coincident red (Cytotox red) and green (HIV-VLP-GFP) objects. Since ×10 magnification was used, single viral particles were undetectable; HIV-VLPs can be visualized only when multiple particles were concentrated in NETs or in cells.


The replication-competent GFP-encoding infectious molecular clone (pNLENG1i-BaL.ecto)46 was derived from pNLENG1-ires47 to express heterologous BaL env gene sequences in an isogenic backbone following the strategy previously described.48,49 This reporter virus, collectively referred to as Env-IMC-GFP, expresses GFP upon infection of HIV-1-susceptible target cells.

Generation of CD4+ T cells

Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll density gradient centrifugation. As described before,50 CD4+ T cells were purified from PBMCs using magnetic negative selection (Miltenyi Biotech), cultured in Xvivo15 supplemented with 10% inactivated human AB serum, and activated in vitro with phytohemagglutinin (2.5 µg/ml; Sigma, St. Louis, MO, USA) and IL-2 (50 U/ml) (AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: Human rIL-2 from Dr. Maurice Gately, Hoffmann-La Roche, Inc.)51 for 1 to 3 days prior to HIV infection. Purity higher than 98% was obtained after CD4+ T cell magnetic isolation.

NET isolation

Isolation of NETs was adapted from Najmeh et al.28 Genital neutrophils were stimulated with calcium ionophore (Sigma; 25 µM) for 1 h.27 After incubation, cells and supernatants were collected and centrifuged at 500 × g for 5 min to generate a cell pellet. Supernatants were then transferred to a new tube and centrifuged for 18,000 × g for 10 min at 4 °C, to generate a DNA pellet containing NETs. DNA content in NET and control conditions was quantified, resuspended in PBS, and plated in round bottom ultra-low attachment 96-well plates (Corning) in triplicates. Plates were kept overnight at 4 °C and HIV inactivation assays performed the next day.

HIV inactivation assays

NETs and DNA controls were incubated with replication-competent GFP-encoding HIV (multiplicity of infection = 0.5) for 1 h. For some experiments, DNAse (Worthington Biochemical) was added after this incubation period for 15 min to degrade NETs and release any potentially infectious virions. CD4+ T cells were then added to the wells, spun down to ensure contact with NETs, and incubated for 2 additional hours at 37 °C. After incubation, residual virus was washed away and fresh media were added to each well. Cell cultures were maintained for 7 days, with half of the well media collected and replaced with fresh media on day 3. This reporter virus expresses GFP upon infection of HIV-1-susceptible target cells. GFP expression levels were measured by fluorescence microscopy with the Incucyte Zoom system. Levels of p24 were measured in conditioned media by p24 ELISA (Advanced Bioscience Laboratories, Rockville, MD, USA) on days 3 and 7 after infection.


Data analysis was performed using the GraphPad Prism 5.0 software. A two-sided P value <0.05 was considered statistically significant. Comparison of two groups was performed with the non-parametric Mann–Whitney U test or Wilcoxon's matched-pairs test. Comparison of three or more groups was performed applying the non-parametric Kruskal–Wallis followed by Dunn’s post-test.